The Role of Mesenchymal Stem Cells and Imatinib in the Process of Liver Fibrosis Healing Through and Axes

Overview

Journal Rep Biochem Mol Biol

Specialty Biochemistry

Date 2024 Feb 6

PMID 38317807

Authors

Parisa Varjavand

Ardeshir Hesampour

Affiliations

Soon will be listed here.

Abstract

Background: Persistent liver damage contributes to the development of liver fibrosis, marked by an accumulation of extracellular matrix. Macrophages play a pivotal role in this process, with the CCL2-CCR2 and CX3CR1-CX3CL1 axes serving as key regulators of macrophage recruitment, liver infiltration, and differentiation. In this study, utilizing a rat model of carbon tetrachloride (CCL4)-induced liver fibrosis, we aimed to investigate the impact of imatinib and bone marrow-derived mesenchymal stem cells (BM-MSCs) on the expression of these axis.

Methods: Sixteen Sprague-Dawley rats were divided into four groups: healthy, liver fibrosis, imatinib-recipient, and BM-MSC-recipient. Treatment effects were evaluated using histopathology and Sirus-red staining. Quantitative real-time PCR was employed to analyze changes in the expression of the genes CCL2, CCR2, CX3CL1, and CX3CR1.

Results: Histopathological assessments revealed the efficacy of imatinib and BM-MSCs in mitigating liver fibrosis. Our findings demonstrated a significant reduction in CCL2 and CCR2 expression in both imatinib and BM-MSCs treatment groups compared to the liver fibrosis group. Conversely, the gene expression of CX3CL1 and CX3CR1 increased in both therapeutic groups compared to the liver fibrosis groups.

Conclusions: The notable decrease in CCL2-CCR2 genes in both therapeutic groups suggests that BM-MSCs and imatinib may contribute to a decline in inflammatory macrophages within the liver. The lower CCL2-CCR2 expression in imatinib-recipient rats indicates better efficacy in modulating the recruitment of inflammatory macrophages. The elevated expression of CX3CL1 in BM-MSC-recipient rats suggests a greater impact on the polarization of LY6Chigh (inflammatory) to LY6Clow (anti-inflammatory) macrophages, warranting further investigation.

References

Triantafyllou E, Woollard K, McPhail M, Antoniades C, Possamai L . The Role of Monocytes and Macrophages in Acute and Acute-on-Chronic Liver Failure. Front Immunol. 2019; 9:2948. PMC: 6302023. DOI: 10.3389/fimmu.2018.02948. View

Khomich O, Ivanov A, Bartosch B . Metabolic Hallmarks of Hepatic Stellate Cells in Liver Fibrosis. Cells. 2019; 9(1). PMC: 7016711. DOI: 10.3390/cells9010024. View

Zhang M, Liu H, Huang K, Peng Y, Tao Y, Zhao C . Fuzheng Huayu Recipe Prevented and Treated CCl4-Induced Mice Liver Fibrosis through Regulating Polarization and Chemotaxis of Intrahepatic Macrophages via CCL2 and CX3CL1. Evid Based Complement Alternat Med. 2020; 2020:8591892. PMC: 7714560. DOI: 10.1155/2020/8591892. View

Mohammadi Gorji S, Karimpor Malekshah A, Hashemi-Soteh M, Rafiei A, Parivar K, Aghdami N . Effect of mesenchymal stem cells on Doxorubicin-induced fibrosis. Cell J. 2013; 14(2):142-51. PMC: 3584430. View

Khalil M, El-Demerdash R, Elminshawy H, Mehanna E, Mesbah N, Abo-Elmatty D . Therapeutic effect of bone marrow mesenchymal stem cells in a rat model of carbon tetrachloride induced liver fibrosis. Biomed J. 2020; 44(5):598-610. PMC: 8640564. DOI: 10.1016/j.bj.2020.04.011. View

Yoshiji H, Noguchi R, Kuriyama S, Ikenaka Y, Yoshii J, Yanase K . Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol. 2004; 288(5):G907-13. DOI: 10.1152/ajpgi.00420.2004. View

Poulsen K, Cajigas-Du Ross C, Chaney J, Nagy L . Role of the chemokine system in liver fibrosis: a narrative review. Dig Med Res. 2022; 5. PMC: 9632683. DOI: 10.21037/dmr-21-87. View

Mansour M, Greish S, El-Serafi A, Abdelall H, El-Wazir Y . Therapeutic potential of human umbilical cord derived mesenchymal stem cells on rat model of liver fibrosis. Am J Stem Cells. 2019; 8(1):7-18. PMC: 6526361. View

Tacke F . Functional role of intrahepatic monocyte subsets for the progression of liver inflammation and liver fibrosis in vivo. Fibrogenesis Tissue Repair. 2012; 5(Suppl 1):S27. PMC: 3368797. DOI: 10.1186/1755-1536-5-S1-S27. View

10.

Kuo W, Yu M, Lee J, Tsai C, Chen T, Chen M . Imatinib mesylate improves liver regeneration and attenuates liver fibrogenesis in CCL4-treated mice. J Gastrointest Surg. 2011; 16(2):361-9. DOI: 10.1007/s11605-011-1764-7. View

11.

Marcellin P, Kutala B . Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int. 2018; 38 Suppl 1:2-6. DOI: 10.1111/liv.13682. View

12.

Puengel T, Krenkel O, Kohlhepp M, Lefebvre E, Luedde T, Trautwein C . Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury. PLoS One. 2017; 12(9):e0184694. PMC: 5598992. DOI: 10.1371/journal.pone.0184694. View

13.

Sacchi P, Cima S, Corbella M, Comolli G, Chiesa A, Baldanti F . Liver fibrosis, microbial translocation and immune activation markers in HIV and HCV infections and in HIV/HCV co-infection. Dig Liver Dis. 2014; 47(3):218-25. DOI: 10.1016/j.dld.2014.11.012. View

14.

Baghaei K, Hashemi S, Tokhanbigli S, Asadi Rad A, Assadzadeh-Aghdaei H, Sharifian A . Isolation, differentiation, and characterization of mesenchymal stem cells from human bone marrow. Gastroenterol Hepatol Bed Bench. 2017; 10(3):208-213. PMC: 5660271. View

15.

Sakaida I, Terai S, Yamamoto N, Aoyama K, Ishikawa T, Nishina H . Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology. 2004; 40(6):1304-11. DOI: 10.1002/hep.20452. View

16.

Scott C, Zheng F, De Baetselier P, Martens L, Saeys Y, De Prijck S . Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells. Nat Commun. 2016; 7:10321. PMC: 4737801. DOI: 10.1038/ncomms10321. View

17.

Karlmark K, Zimmermann H, Roderburg C, Gassler N, Wasmuth H, Luedde T . The fractalkine receptor CX₃CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology. 2010; 52(5):1769-82. DOI: 10.1002/hep.23894. View

18.

Karlmark K, Weiskirchen R, Zimmermann H, Gassler N, Ginhoux F, Weber C . Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology. 2009; 50(1):261-74. DOI: 10.1002/hep.22950. View

19.

Kreutzman A, Yadav B, Brummendorf T, Gjertsen B, Lee M, Janssen J . Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. Oncoimmunology. 2019; 8(9):e1638210. PMC: 6685516. DOI: 10.1080/2162402X.2019.1638210. View

20.

Baeck C, Wehr A, Karlmark K, Heymann F, Vucur M, Gassler N . Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut. 2011; 61(3):416-26. DOI: 10.1136/gutjnl-2011-300304. View